spacer
home > > spring 2018 > money matters
PUBLICATIONS


Money Matters


 

EPC: What are some of the challenges sites face when trying to be paid?

Dave Espenshade: A site’s ability to receive accurate and timely payments from sponsors or CROs is one of the most challenging processes it faces while conducting clinical trials. In fact, we often hear that payment terms are the biggest driver in a site’s ability to support a clinical study.

There are many reasons why this is such a challenge, with invoice adjudication being the biggest contributor to the limited transparency in the payment process. From a sponsor or CRO perspective, invoices are arriving in a variety of formats and often at different intervals. This causes a number of inconsistencies that their finance teams need to unravel to determine what work was performed, what rate was contracted, and what needs to be paid. This is a complex and difficult process, and, as a result, many sponsors and CROs pay their sites on a quarterly basis to keep up with this workload.

This time gap between services rendered and payment, along with the errors that often occur with payments, is one of the biggest challenges that sites face.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dave Espenshade is Vice President of CRO Partnerships at Greenphire. In his role, he leads the efforts to broaden the use of Greenphire’s solution suite among global CRO partners. Dave has more than two decades of experience in the software and life sciences industries and a demonstrated expertise in establishing successful partnerships between industryleading global CROs and software providers.
spacer
Dave Espenshade
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Controlant now providing monitoring and Supply Chain Visibility for Pfizer-BioNTech Covid-19 Vaccine distribution and storage

December 15, 2020, 6 AM ET/11am GMT – Kopavogur, Iceland and San Francisco, CA – Controlant, a leader in real-time supply chain monitoring and visibility technologies for heavily regulated industries, such as pharmaceuticals & life sciences and food & beverage sectors, today announced it is providing its monitoring and Supply Chain Visibility services to Pfizer, in relation to the delivery of Pfizer’s mRNA-based Pfizer-BioNTech COVID-19 vaccine’s global distribution.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement